Скачать или смотреть Quo-Lab analyzer for HbA1c practical| شرح عملي لفحص السكر التراكمي

Quo-Lab HbA1c is a semi-automated desktop point-of-care analyzer for measuring glycated hemoglobin (HbA1c).
The semi-automated analyzer has been designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand the low cost of operation and ease of use.
-Semi-automated analyzer
-Results in just four minutes
-4 µl sample size required
-Dimensions: 95 x 205 x 135mm

Subscribe for more practical videos:
   / @hassanawad-labtalk  

The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated conclusively that risks for complications in patients with diabetes are directly related to glycemic control, as measured by glycated hemoglobin (GHb). Many diabetes organizations worldwide now recommend GHb targets in terms of DCCT/ UKPDS hemoglobin A1c (HbA1c). The National Glycohemoglobin Standardization Program (NGSP) was implemented to enable laboratories to report DCCT/UKPDS-traceable GHb/HbA1c results. The number of methods and laboratories certified by the NGSP as traceable to the DCCT has steadily increased. Proficiency testing results show marked improvement in the comparability of GHb results.
The Diabetes Control and Complications Trial (DCCT) is a multicenter, randomized, clinical study designed to determine whether an intensive treatment regimen directed at maintaining blood glucose concentrations as close to normal as possible will affect the appearance or progression of early vascular complications in patients with insulin-dependent diabetes mellitus (IDDM).

The NIDDK funded the landmark Diabetes Control and Complications Trial (DCCT) to see if people with type 1 diabetes who kept their blood glucose levels as close to normal as safely possible with intensive diabetes treatment (three or more shots of insulin per day or an insulin pump with self-monitoring of blood glucose at least four times per day) could slow the development of eye, kidney, and nerve disease, compared with people who used the conventional treatment at the time of the study (one or two shots of insulin per day with daily self-monitoring of urine or blood glucose). The DCCT ended after 10 years in 1993—a year earlier than planned—when the study proved that participants who kept their blood glucose levels close to normal greatly lowered their chances of having eye, kidney, and nerve disease.
قام NIDDK بتمويل التجربة التاريخية للسيطرة على مرض السكري ومضاعفاته (DCCT) لمعرفة ما إذا كان الأشخاص المصابون بداء السكري من النوع 1 الذين حافظوا على مستويات السكر في الدم قريبة من المعدل الطبيعي بأمان ممكن من خلال العلاج المكثف لمرض السكري (ثلاث جرعات أو أكثر من الأنسولين يوميًا أو الأنسولين الضخ مع المراقبة الذاتية لنسبة الجلوكوز في الدم أربع مرات على الأقل يوميًا) يمكن أن يبطئ من تطور أمراض العين والكلى والأعصاب ، مقارنة بالأشخاص الذين استخدموا العلاج التقليدي في وقت الدراسة (جرعة واحدة أو جرعتين من الأنسولين لكل يوم مع المراقبة الذاتية اليومية للبول أو الجلوكوز في الدم). انتهى اختبار DCCT بعد 10 سنوات في عام 1993 - قبل عام مما كان مخططا له - عندما أثبتت الدراسة أن المشاركين الذين حافظوا على مستويات السكر في الدم قريبة من المعدل الطبيعي قللوا بشكل كبير من فرص الإصابة بأمراض العين والكلى والأعصاب